Aichi Cancer Center and Fujitsu jointly developed new AI solution to support physicians in efficiently choosing medical treatment
Aichi Cancer Center and Fujitsu have announced the development of an artificial intelligence (AI) based solution able to select effective medical treatment from a wide range of drugs based on patients’ individual cancer types and various genomic variants.
The effectiveness of the new solution has been verified in clinical trials by physicians at Aichi Cancer Center.
With current cancer genomic medicine in Japan, treatment plans are considered based on the patients’ unique circumstances, including the type of cancer and the actionable genomic variants detected in cancer cells.
Continue reading… “Fujitsu to offer AI-based personalised cancer treatment in Japan”
